Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
Status:
Terminated
Trial end date:
2019-07-22
Target enrollment:
Participant gender:
Summary
This research is being done to find out the toxicity and efficacy of a combination of
Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant
maintenance therapy for non-remission AML and to see the overall diseases free survival,
relapse, and GVHD after treatment.